Eptinezumab-jjmr (referred to as eptinezumab hereafter; Vyepti™) is a humanised 
monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) and 
blocks its binding to the receptor. CGRP is believed to play a major role in the 
pathophysiology of migraine. Eptinezumab, delivered by intravenous (IV) 
administration, is being developed by Lundbeck Seattle BioPharmaceuticals for 
the prevention of migraine. In February 2020, eptinezumab was approved in the 
USA for the preventive treatment of migraine in adults. This article summarizes 
the milestones in the development of eptinezumab leading to this first approval.